Theorem Clinical Research

R&D Trends

PharmAthene awarded $28.1M to develop thermostable anthrax vaccine

Thursday, September 11, 2014 01:36 PM

PharmAthene, an Annapolis, Md.-based biodefense company developing medical countermeasures against biological and chemical threats, has announced the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has awarded the company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next-generation anthrax vaccine based on the company's proprietary rPA anthrax vaccine technology platform.

More... »


Report: Psoriatic arthritis market will reach more than $3.5B in 2023

Thursday, September 11, 2014 01:28 PM

The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in 2023, due to the continued uptake of premium-price biologics and novel therapies expected to launch during the 2013 to 2023 forecast period, according to Burlington, Mass.-based Decision Resources Group.

More... »


Seattle Genetics, Genmab enter into antibody-drug conjugate collaboration

Thursday, September 11, 2014 01:20 PM

Seattle Genetics, a biotech company focused on development and commercialization of innovative antibody-based therapies for cancer, and Genmab, a Denmark-based international biotech company specializing in differentiated human antibody therapeutics for cancer, have entered into an additional antibody-drug conjugate (ADC) collaboration.

More... »

Report: clinical trials will continue to play a key role in oncology device market

Wednesday, September 10, 2014 03:03 PM

The U.S. interventional oncology device market will see strong growth, reaching a value of $760 million by 2023, according to Decision Resources Group. Rising cancer incidence rates, combined with the ineffectiveness of chemotherapy and demand for less invasive procedures, will support interventional oncology device uptake.

More... »

NeuroVive Pharmaceutical, Oncore Biopharma ink $150M agreement

Wednesday, September 10, 2014 03:01 PM

NeuroVive Pharmaceutical, a Swedish mitochondrial medicine company, has signed an exclusive global out-licensing agreement with the Pennsylvania-based OnCore BioPharma for the development and commercialization of NeuroVive’s drug candidate NVP018 for oral treatment of chronic hepatitis B virus (HBV) infection. The agreement could give NeuroVive a total of $150 million in conditional milestone payments, plus royalties on future drug sales.

More... »

GSK partners with research councils in U.K. and South Africa on non-communicable diseases

Wednesday, September 10, 2014 02:48 PM

GlaxoSmithKline has announced an $8 million collaboration with the U.K. and South African Medical Research Councils, to support much-needed research into non-communicable diseases (NCDs) in Africa, as part of GSK’s Africa NCD Open Lab initiative. 

More... »

Oregon associations Oregon Bio and TAO collaborate

Monday, September 8, 2014 01:54 PM

Oregon Bioscience Association (Oregon Bio), a nonprofit member association based in Oregon, and the Technology Association of Oregon (TAO) are collaborating to cultivate Oregon's health information technologies, personal digital health products, bioinformatics and health analytics industries. Both organizations will coordinate support for companies, entrepreneurs, research institutes and care organizations to expand Oregon's life sciences and digital health economy.

More... »

Redx Pharma, AstraZeneca collaborate

Thursday, September 4, 2014 12:34 PM

Redx Pharma, a U.K.-based group focused on early stage drug discovery and development, has entered into a research collaboration with AstraZeneca to discover and develop new molecules targeting a genetic driver of tumor growth and survival.

More... »

Infinity, AbbVie partner to develop, commercialize oncology drug duvelisib

Thursday, September 4, 2014 12:28 PM

Infinity Pharmaceuticals, based in Cambridge, Mass., and AbbVie have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, to treat cancer.

More... »

Report: Children’s cancer death rates in U.K. drop more than 20% in 10 years

Wednesday, September 3, 2014 12:48 PM

The rate of children dying from cancer in the U.K. has dropped 22% in the last decade, according to new figures published by Cancer Research U.K.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs